ALNA after hours: Allena Pharmaceuticals NASDAQ $0.075, watch catalysts

ALNA stock moved as one of the most active names in after-hours trading on 09 Feb 2026, trading at USD 0.075 on the NASDAQ in the United States. Volume spiked to 252,311,606 shares as traders reacted to micro-cap biotech flows and sector rotation in Healthcare. Allena Pharmaceuticals, Inc. (ALNA) remains a clinical-stage biotechnology company focused on oral enzyme therapies with lead candidate ALLN-346. Investors are watching near-term catalysts, cash runway metrics and liquidity as drivers for further price moves in after-hours trading.

ALNA stock price action (after hours, most active)

ALNA stock is trading after hours on NASDAQ at USD 0.075, up 3.16% on the session with a day range of USD 0.06–0.1459. Volume reported at 252,311,606 shares signals outsized retail interest and adds volatility in after-hours trading for this United States-listed biotech.

ALNA stock fundamentals and Meyka grade

Allena Pharmaceuticals (ALNA) reports trailing EPS of -0.638 and a negative PE of -0.12, reflecting development-stage losses and limited revenue. Meyka AI rates ALNA with a score out of 100: 62.57 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 comparison, sector and industry metrics, financial growth, key ratios and analyst consensus. Key balance-sheet metrics include cash per share USD 0.92, book value per share USD 0.58, and a current ratio of 2.11, which supports a short-term runway but highlights development-stage funding needs.

ALNA stock catalysts and risks

Near-term catalysts for ALNA stock include clinical updates for ALLN-346 and cash runway news; those events can move price sharply. Major risks are continued operating losses, low liquidity in normal hours despite large intraday volume, and biotech sector sensitivity to broader Healthcare flows.

ALNA stock technicals and volume

Technically, ALNA stock shows a wide intraday range and very high traded volume, suggesting short-term momentum trading dominates. The gap between the session low USD 0.06 and high USD 0.1459 signals large order swings and elevated volatility compared with typical biotech peers on NASDAQ.

ALNA stock forecast and analyst view

Meyka AI’s forecast model projects a 12-month central target of USD 0.12, which implies an upside of 60.00% vs the current price USD 0.075; forecasts are model-based projections and not guarantees. Market consensus coverage is limited, so trader reaction to news from mainstream outlets like Bloomberg and Reuters can swing short-term sentiment source source. For a consolidated company lookup, see Meyka AI’s ALNA profile for live metrics.

Final Thoughts

Key takeaways for ALNA stock on 09 Feb 2026 after hours: the share price sits at USD 0.075 on NASDAQ with outsized session volume 252,311,606, reflecting speculative interest in this small-cap biotechnology name. Fundamentals show development-stage losses (EPS -0.64) but a manageable short-term balance sheet with cash per share USD 0.92 and current ratio 2.11. Meyka AI’s forecast model projects a 12-month target of USD 0.12, implying 60.00% upside from USD 0.075, while downside scenarios tied to trial setbacks or funding needs could push the price materially lower. Meyka AI rates ALNA with a score out of 100 at 62.57 (Grade B, HOLD); this reflects mixed signals from sector performance, financials, and limited analyst coverage. Traders should treat ALNA stock as a high-volatility, event-driven biotech play and size positions accordingly. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.